[Federal Register Volume 62, Number 220 (Friday, November 14, 1997)]
[Notices]
[Pages 61130-61131]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-30029]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 97M-0453]


HealthTronics, Inc.; Premarket Approval of Lithotron<SUP>TM</SUP> 
Lithotripsy System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing its 
approval of the application submitted by HealthTronics, Inc., Marietta, 
GA, for premarket approval, under the Federal Food, Drug, and Cosmetic 
Act (the act), of the LithoTron<SUP>TM</SUP> Lithotripsy System. FDA's 
Center for Devices and Radiological Health (CDRH) notified the 
applicant, by letter of July 21, 1997, of the approval of the 
application.

DATES: Petitions for administrative review by December 15, 1997.

ADDRESSES: Written requests for copies of the summary of safety and 
effectiveness data and petitions for administrative review, to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, 
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Russell P. Pagano, Center for Devices 
and Radiological Health (HFZ-470), Food and Drug Administration, 9200 
Corporate Blvd., Rockville, MD 20850, 301-594-2194.

SUPPLEMENTARY INFORMATION: On May 16, 1997, HealthTronic, Inc., 
Marietta, GA 30060, submitted to CDRH an application for premarket 
approval of the LithoTron<SUP>TM</SUP> Lithotripsy System. The device 
is an extracorporeal shockwave lithotripter and is indicated for use in 
patients with renal and upper ureteral calculi between 4 and 20 
millimeters in size.
    In accordance with the provisions of section 515(c)(2) of the the 
act (21 U.S.C. 360e(c)(2)) as amended by the Safe Medical Devices Act 
of 1990, this premarket approval was not referred to the 
Gastroenterology and Urology Devices Panel of the Medical Devices 
Advisory Committee, an FDA advisory committee, for review and 
recommendation because the information in the PMA substantially 
duplicates information previously reviewed by this panel.
    On July 21, 1997, CDRH approved the application by a letter to the 
applicant from the Deputy Director of Clinical and

[[Page 61131]]

Review Policy of the Office of Device Evaluation, CDRH.
    A summary of the safety and effectiveness data on which CDRH based 
its approval is on file in the Dockets Management Branch (address 
above) and is available from that office upon written request. Requests 
should be identified with the name of the device and the docket number 
found in brackets in the heading of this document.

Opportunity for Administrative Review

    Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any 
interested person to petition, under section 515(g) of the act, for 
administrative review of CDRH's decision to approve this application. A 
petitioner may request either a formal hearing under 21 CFR part 12 of 
FDA's administrative practices and procedures regulations or a review 
of the application and CDRH's action by an independent advisory 
committee of experts. A petition is to be in the form of a petition for 
reconsideration under 21 CFR 10.33(b). A petitioner shall identify the 
form of review requested (hearing or independent advisory committee) 
and shall submit with the petition supporting data and information 
showing that there is a genuine and substantial issue of material fact 
for resolution through administrative review. After reviewing the 
petition, FDA will decide whether to grant or deny the petition and 
will publish a notice of its decision in the Federal Register. If FDA 
grants the petition, the notice will state the issue to be reviewed, 
the form of the review to be used, the persons who may participate in 
the review, the time and place where the review will occur, and other 
details.
    Petitioners may, at any time on or before December 15, 1997, file 
with the Dockets Management Branch (address above) two copies of each 
petition and supporting data and information, identified with the name 
of the device and the docket number found in brackets in the heading of 
this document. Received petitions may be seen in the office above 
between 9 a.m. and 4 p.m., Monday through Friday.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (secs. 515(d), 520(h), (21 U.S.C. 360e(d), 360j(h))) and under 
authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) 
and redelegated to the Director, Center for Devices and Radiological 
Health (21 CFR 5.53).

    Dated: October 17, 1997.
Joseph A. Levitt,
Deputy Director for Regulations Policy, Center for Devices and 
Radiological Health.
[FR Doc. 97-30029 Filed 11-13-97; 8:45 am]
BILLING CODE 4160-01-F